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Objective: During myocardial revascularization, some surgeons (particularly in the
United Kingdom) use intermittent crossclamping with fibrillation as an alternative
to cardioplegia. We recently showed that intermittent crossclamping with fibrilla-
tion has an intrinsic protection equivalent to that of cardioplegia. In this study we
hypothesized that arrest, rather than fibrillation, during intermittent crossclamping
may be beneficial. Because esmolol, an ultra-short-acting β-blocker, is known to
attenuate myocardial ischemia-reperfusion injury, we compared the protective
effect of esmolol arrest with that of intermittent crossclamping with fibrillation and
conventional cardioplegia (St Thomas’ Hospital solution).
Methods: Isolated rat hearts were Langendorff perfused at either constant flow (14
mL/min) or constant pressure (75 mm Hg) with oxygenated Krebs-Henseleit bicar-
bonate buffer (37°C), and left ventricular developed pressure was assessed. In study
1 (constant flow perfusion) 8 groups (n = 6 hearts per group) were studied: (1) 40
minutes of global ischemia; (2) 2 minutes of St Thomas’ Hospital infusion and 40
minutes of ischemia; (3) multidose (every 10 minutes) infusions of St Thomas’
Hospital solution during 40 minutes of ischemia; (4) 2 minutes of esmolol infusion
and 40 minutes of ischemia; (5) multidose (every 10 minutes) esmolol infusions
during 40 minutes of ischemia; (6) continuous infusion of esmolol for 40 minutes
during coronary perfusion; (7) intermittent (4 × 10 minutes) ischemia with ventric-
ular fibrillation; and (8) intermittent (4 × 10 minutes) ischemia preceded by inter-
mittent esmolol administration. All protocols were followed by 60 minutes of reper-
fusion. Further experiments (study 2) examined the esmolol administration method
in hearts perfused by constant pressure.
Results: An optimal arresting dose of 1.0 mmol/L esmolol was established. In study
1 recovery of left ventricular developed pressure (expressed as percentage of pre-
ischemic value) was 7% ± 4%, 28% ± 8%, 70% ± 5%, 8% ± 1%, 90% ± 4%, 65%
± 3%, 71% ± 5%, and 76% ± 5% in groups 1 to 8, respectively. Intermittent esmolol
arrest with global ischemia provided equivalent myocardial protection to intermit-
tent crossclamping with fibrillation, continuous esmolol perfusion, and multidose St
Thomas’ Hospital solution. Surprisingly, multidose esmolol infusion was more pro-
tective than all other treatments. In further experiments (study 2) optimal recovery
was obtained with multiple esmolol infusions (by constant flow or constant pres-
sure), but continuous esmolol infusion (at constant flow) was less effective than
constant pressure infusion.
Conclusions: Intermittent arrest with esmolol did not enhance protection of inter-
mittent crossclamping with fibrillation; however, multiple esmolol infusions during
global ischemia provided improved protection. Administration (constant flow or
constant pressure) of arresting solutions influenced outcome only during continu-
ous infusion. Multidose esmolol arrest may be a beneficial alternative to intermit-
tent crossclamping with fibrillation or conventional cardioplegia.
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Myocardial protection during cardiacoperations is most commonly achievedby hyperkalemic cardioplegic arrest1,2;however, a minority of surgeons, partic-ularly in the United Kingdom, continueto favor the technique of intermittent
ventricular fibrillation (VF), either with3 or without4 aortic
crossclamping. Recent clinical studies5,6 have shown that
intermittent crossclamp (ventricular) fibrillation (ICCF) pro-
vides equivalent myocardial protection to cold cardioplegia. In
these studies, however, the cumulative ischemic duration dur-
ing ICCF was invariably shorter than that of the comparative
ischemia associated with cardioplegic arrest; hence, it was
unclear whether this shorter ischemic duration was associated
with reduced injury. We7 have recently demonstrated, in an
experimental study, that intermittent global ischemia either
alone or with VF does provide an intrinsic protection. In addi-
tion, VF did not appear to exacerbate any ischemic injury. This
suggested the possibility that rapid arrest with a cardioplegic
agent, rather than ischemic arrest or VF (ICCF), might further
improve myocardial protection.
It is known that β-adrenergic antagonists (β-blockers)
attenuate the extent of myocardial injury during ischemia and
reperfusion.8,9 The negative inotropic and chronotropic effects
of these drugs is thought to concomitantly reduce myocardial
oxygen consumption, decrease sympathetic tone, reduce
myocardial substrate use, and stabilize cell membranes,10,11
thereby exerting a beneficial effect on ischemic myocardium.
Most β-blockers, however, have prolonged negative inotropic
properties,12 with a half-life of many hours, which limits their
use during cardiac operations. In contrast, the ultra-short-act-
ing and cardioselective β-blocker esmolol has a half-life of a
few minutes,13 which allows its negative inotropic effects to be
abolished rapidly after reduction or cessation of infusion. This
short half-life of esmolol led Sweeney and Frazier14 to use
high-dose esmolol infusion in hearts of patients with compro-
mised left ventricular (LV) function who were supported by an
LV assist device to suppress cardiac inotropy and chronotropy
during myocardial revascularization. Subsequently, experi-
mental15,16 and clinical17-20 studies have shown that esmolol
can be used to obtain minimal myocardial contraction during
cardiac operations while maintaining continuous normother-
mic coronary perfusion to avoid ischemia. With this technique,
myocardial protection was equivalent to or better than that
obtained with cold crystalloid or blood cardioplegia.
Therefore, we hypothesized that a combination of
esmolol arrest with intermittent global ischemia would
enhance the protection observed with ICCF, and we con-
ducted a study to examine the protective effect of intermit-
tent esmolol arrest and to compare this effect with ICCF and
conventional cardioplegic solutions. As a consequence of
this, a further study was conducted to examine the optimal
method for infusion of the protective solutions.
Materials and Methods
Animals
Adult male Wistar rats (240-300 g body weight) were used (Bantin
and Kingman, Hull, United Kingdom). All animals received
humane care in accordance with the “Guidance on the Operation
of the Animals (Scientific Procedures) Act of 1986” published by
Her Majesty’s Stationery Office (London, England). Rats were
anesthetized with 95% oxygen/5% carbon dioxide bubbled
through diethyl ether and were then anticoagulated with heparin
(1000 IU/kg body weight) administered intravenously.
Heart Isolation and Perfusion
Hearts were rapidly excised from the anesthetized rats and
immersed in cold (4°C) Krebs-Henseleit buffer (KHB). The aorta
was then cannulated, and the heart was perfused at 37°C in the
Langendorff mode, as previously described.7 Hearts were perfused
at either constant pressure (75 mm Hg) or constant flow (14
mL/min) by means of a peristaltic pump (Gilson Minipuls 3;
Gilson Company, Inc, Lewis Center, Ohio). A unipolar electrocar-
diogram (ECG) was obtained through a silver electrode inserted
into the free wall of the left ventricle and a reference electrode con-
nected to the aortic cannula; the ECG was continuously recorded
throughout the protocol. All hearts were subjected to an equilibra-
tion period (20 minutes) of aerobic perfusion, and baseline read-
ings of LV systolic pressure (in millimeters of mercury), LV end-
diastolic pressure (LVEDP; in millimeters of mercury), heart rate
(in beats per minute), and coronary flow (in milliliters per minute)
were taken. LV developed pressure (LVDP) was calculated as the
LV systolic pressure minus LVEDP. Coronary flow was measured
by timed collections of the coronary effluent. The development of
contracture during ischemia (when of sufficient duration) was
recorded. Infusion volume of cardioplegic solution was measured
by collecting coronary effluent during infusion of cardioplegic
solution.
Exclusion Criteria
Hearts not satisfying preassigned exclusion criteria at the time of
the baseline readings were excluded from the study. The accept-
able ranges for LVDP, heart rate, and coronary flow were as fol-
lows: greater than 100 mm Hg, greater than 220 beats/min, and 8
to 16 mL/min, respectively.
Perfusion Medium
This was a modified KHB with the following composition: NaCl,
118.5 mmol/L; NaHCO3, 25.0 mmol/L; KCl, 4.8 mmol/L; MgSO4,
1.2 mmol/L; CaCl2, 1.4 mmol/L; and glucose, 11.0 mmol/L. The
buffer was prepared daily, filtered through a 5-µm pore size cellulose
nitrate membrane filter before use, and continuously gassed with
95% oxygen/5% carbon dioxide mixture to give a pH of 7.4 at 37°C.
Preparation and Administration of Esmolol and
Cardioplegic Solution
Esmolol (Brevibloc; Baxter Pharmaceuticals, Crowthorne,
Berkshire, United Kingdom) was provided in vials containing 10
mL of a 250 mg/mL solution. Preliminary studies were carried out
to determine a dose-response curve for esmolol; 5 dilutions of the
original esmolol solution (1:3, 1:10, 1:30, 1:100, and 1:300 dilut-
ed in oxygenated KHB) were infused with an electronic syringe
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pump (Razel Scientific Instruments Inc, Stamford, Conn) attached
to a multiway aortic cannula at an infusion rate of 0.215 mL/min.
Hearts were perfused at a constant flow rate of 14 mL/min; conse-
quently, the final concentrations of esmolol reaching the heart were
approximately 3.0, 1.0, 0.3, 0.1, and 0.03 mmol/L, respectively. As
a result of these dose-response studies, subsequent esmolol cardio-
plegic solution was prepared by diluting 1.5 mL of esmolol (250
mg/mL) in 1000 mL of oxygenated KHB, giving a final esmolol
concentration of 1.0 mmol/L.
The St Thomas’ Hospital cardioplegic solution No. 2 (STH2)
was prepared daily with the following composition: NaCl, 110.0
mmol/L; MgCl2· 6H2O, 16.0 mmol/L; KCl, 16.0 mmol/L; CaCl2·
2H2O, 1.2 mmol/L; and NaHCO3, 10.0 mmol/L. The pH was
adjusted to 7.8 at 37°C, and the solution was filtered through a 5-
µm cellulose nitrate filter before use.
Each solution was delivered at 37°C and at either a constant
pressure of 45 mm Hg or a constant flow rate of 14 mL/min for 2
minutes each infusion.
Induction and Termination of VF
VF was induced with an electrical fibrillator (model G570,
Department of Bioengineering, St Thomas’ Hospital) by passing
alternating current through 2 silicone-coated silver electrodes, one
attached to the apex of the ventricle and the other grounded on the
aortic cannula. The minimum voltage necessary to achieve an
alternating current that maintained VF was used. If VF occurred
during reperfusion or did not terminate spontaneously after the
fibrillator was turned off, it was terminated by the use of a defi-
brillator (model G 434, Department of Bioengineering, St Thomas’
Hospital).
Preliminary Study: Determination of Dose-Response
Curve for Esmolol
Before starting the following protocols, we determined the dose-
response curve for esmolol. Hearts were randomly assigned to one
of 5 esmolol concentration groups (ie, 0.03, 0.1, 0.3, 1.0, and 3.0
mmol/L; n = 6 hearts per group). Each concentration of esmolol
was continuously delivered to the heart for 10 minutes, and func-
tion (LVDP) and ECG characteristics (atrial and ventricular rate)
were measured and compared with initial values (expressed as per-
centage of aerobic function).
Perfusion Protocol
After 20 minutes of aerobic equilibration perfusion, hearts were
subjected to 1 of 2 perfusion protocols, as shown in Figure 1.
During the ischemic periods, hearts were immersed in KHB at
37°C with the use of a temperature-controlled, water-jacketed
heart chamber.
Study 1: Myocardial protection with esmolol arrest compared
with STH2 cardioplegia or ICCF. All hearts were perfused at a
constant flow rate of 14 mL/min throughout the protocol and were
randomly assigned to 1 of 8 groups, as listed in Table 1 (n = 6
hearts per group). All protocols were followed by a further 60 min-
utes of reperfusion, when recovery of myocardial function was
measured.
Study 2: Does the method of cardioplegic infusion (constant
flow vs constant pressure) influence protection? In study 1
(above) all hearts were perfused throughout by means of constant
flow, which is a relatively nonphysiologic perfusion technique and
may have affected recovery of function. Consequently, it was
decided to perfuse hearts at constant pressure during aerobic per-
fusion and reperfusion and to determine whether constant flow or
constant pressure infusion influenced protection.
Thus, all hearts were perfused at a constant perfusion pressure
equivalent to 75 mm Hg both before and after global ischemia and
randomized to 1 of 8 groups as listed in Table 2 (n = 6 hearts per
group). All protocols were followed by a further 60 minutes of
reperfusion, when recovery of myocardial function was measured.
Expression of Results
Postischemic recovery of LVDP, heart rate, and coronary flow
were expressed as a percentage of the baseline values; LVEDP was
expressed as an absolute value (in millimeters of mercury). The
following measurements related to contracture during ischemia
were also noted: (1) time to onset of contracture (in minutes); (2)
time to peak contracture (in minutes); and (3) magnitude of peak
contracture (in millimeters of mercury). In addition, we measured
the time to the cessation of mechanical activity (in seconds).
Statistics
Statistical analysis was performed with StatView and
SuperANOVA programs (Abacus Concepts Inc, Berkeley, Calif)
on an Apple Macintosh computer (Apple Computer, Cupertino,
Calif). All data are reported as means ± standard error of the mean.
Comparison between groups was assessed with 1-way analysis of
variance with post hoc analysis by the Fisher protected least sig-
nificant difference test, which allowed for multiple comparisons.
The Student t test (or the Mann-Whitney test when appropriate)
was used to compare 2 means.
Results
Preliminary Study: Determination of Dose-Response
Curve for Esmolol
The esmolol dose-response curve for LVDP, ventricular
rate, and atrial rate (expressed as percentage of initial val-
ues) is shown in Figure 2. Each index demonstrated a nega-
tive sigmoidal curve with increasing concentrations of
esmolol. LVDP and ventricular rate were zero at an esmolol
concentration of 1 mmol/L, whereas atrial rate did not reach
zero until a concentration of 3 mmol/L.
Study 1: Myocardial Protection With Esmolol Arrest
Compared With STH2 Cardioplegia or ICCF
The mean baseline values of LVDP, LVEDP, and heart rate
at the end of 20 minutes of aerobic perfusion in groups 1 to
8 are shown in Table 3. The differences between groups
could be due to chance (P > .02).
Recovery of function
LVDP AND HEART RATE. The changes in recovery of
LVDP over 60 minutes of reperfusion are shown in Figure
3. Hearts subjected to 40 minutes of ischemic arrest (group
1) showed little recovery, as did hearts subjected to a single
2-minute esmolol infusion (group 4). Surprisingly, hearts
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subjected to a single 2-minute STH2 infusion (group 2) only
recovered very slowly and to a low value, but the value was
significantly higher than those for groups 1 and 4 (see
Appendix Table 1). Hearts from other groups recovered
more rapidly and to relatively high values, reaching a
plateau around 10 to 15 minutes after onset of reperfusion;
however, hearts subjected to 40 minutes of continuous
esmolol infusion (group 6) did not reach a plateau of recov-
ery until 40 minutes of reperfusion. The highest and most
rapid recovery was observed in hearts subjected to multiple
esmolol infusions (group 5), and this was significantly high-
er than in all other groups. Interestingly, hearts from groups
3 and 6 to 8 recovered to similar values by 60 minutes of
reperfusion, and thus esmolol infusion before intermittent
global ischemia was equally as protective as ICCF, multiple
infusion of STH2, and continuous infusion of esmolol dur-
ing coronary perfusion.
The percentage recovery of heart rate after 60 minutes of
reperfusion was similar in all groups (not shown).
LVEDP. Changes in postischemic LVEDP during 60
minutes of reperfusion are shown in Figure 4. At the onset
of reperfusion, LVEDP values were moderately elevated,
although continuous coronary perfusion (at 14 mL/min) of
esmolol cardioplegic solution caused an LVEDP of 109 mm
Cardiopulmonary Support and Physiology Bessho and Chambers
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Figure 1. Experimental perfusion protocols. Study 1, All hearts were perfused at a constant flow rate of 14 mL/min
throughout the protocol and were randomly assigned to 1 of 8 groups, as listed in Table 1 (n = 6 hearts per group).
Study 2, All hearts were perfused at a constant perfusion pressure equivalent to 75 mm Hg both before and after
global ischemia and randomized to 1 of 8 groups, as listed in Table 2 (n = 6 hearts per group). All protocols were
followed by 60 minutes of reperfusion, when recovery of myocardial function was measured.
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Hg. Interestingly, poor LVDP recovery (groups 1, 2, and 4)
was associated with rapid and maintained increases in
LVEDP on reperfusion. In contrast, in groups 3 and 5 to 8,
LVEDP declined to relatively normal levels, mirroring the
good recovery in LVDP (Figure 3).
Study 2: Does the Method of Cardioplegic Infusion
(Constant Flow vs Constant Pressure) Influence
Protection?
The mean baseline values of LVDP, coronary flow, LVEDP,
and heart rate after 20 minutes of aerobic perfusion in
groups 1 to 8 are shown in Table 4; the differences between
groups could be due to chance (P > .02). The mean time for
cessation of mechanical activity (in seconds) is also pre-
sented in Table 4 for each group. Hearts subjected to global
ischemia alone (group 1) had significantly prolonged
mechanical activity compared with all other groups;
mechanical quiescence was most rapid in the STH2 groups.
In addition, the mean total volumes of cardioplegic solution
delivered to the heart in the single-dose, multidose, and con-
tinuous groups are shown in Table 4.
Recovery of function
LVDP, CORONARY FLOW, AND HEART RATE. The changes in
LVDP over 60 minutes of reperfusion are shown in Figure
5, A. It is of interest that in hearts subjected to equivalent
protocols in both study 1 and study 2 (groups 1-5), recovery
was more rapid and reached a higher level in study 2, when
aerobic perfusion and reperfusion at constant pressure was
used, indicating an adverse effect of constant flow perfu-
sion. However, hearts subjected to multidose esmolol infu-
sion at constant flow (group 8) recovered to around 100% in
both study 1 and study 2. Complete protection (around
100%) was also observed in hearts subjected to multidose
infusions at a constant pressure of either STH2 or esmolol
cardioplegic solution in study 2; however, protection with
continuous infusion of esmolol cardioplegia at a constant
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TABLE 1. Study 1: Groups into which the hearts were randomly assigned
Group Description
1. C-GI Continuous global ischemia for 40 minutes
2. S-CP Single-dose (2 minutes) STH2 infused before 40 minutes of continuous global ischemia
3. M-CP Multidose (2 minutes) STH2 infused before and every 10 minutes during 40 minutes of global ischemia
4. S-EA Single-dose (2 minutes) esmolol cardioplegia (1 mmol/L esmolol in KHB) infused before 40 minutes of continuous global
ischemia
5. M-EA Multidose (2 minutes) esmolol cardioplegia (1 mmol/L) infused before and every 10 minutes during 40 minutes of global 
ischemia
6. C-EA Continuous coronary perfusion of esmolol cardioplegic solution for 40 minutes (1 mmol/L)
7. I-GI+VF 4 × 10-minute intermittent episodes of global ischemia with VF and 10 minutes of reperfusion in sinus rhythm
8. I-EA+GI 4 × 10-minute intermittent episodes of global ischemia preceded by 2-minute infusions of esmolol cardioplegic solution 
(1 mmol/L) and followed by 8 minutes of reperfusion
STH2, St Thomas’ Hospital solution No. 2; KHB, Krebs-Henseleit buffer. All protocols were followed by a further 60 minutes of reperfusion, when recovery
of myocardial function was measured.
TABLE 2. Study 2: Groups into which the hearts were randomly assigned
Group Description
1. C-GI Continuous global ischemia for 40 minutes
2. S-CP Single-dose (2 minutes) STH2 infused (at 45 mm Hg) before 40 minutes of continuous global ischemia
3. M-CP Multidose (2 minutes) STH2 infused (at 45 mm Hg) before and every 10 minutes during 40 minutes of global ischemia
4. S-EA Single-dose (2 minutes) esmolol cardioplegic solution (1 mmol/L in KHB) infused (at 14 mL/min) before 40 minutes of 
continuous global ischemia
5. M-EA[F] Multidose (2 minutes) esmolol cardioplegic solution (1 mmol/L) infused (at 14 mL/min) before and every 10 minutes 
during 40 minutes of global ischemia
6. M-EA[P] Multidose (2 minutes) esmolol cardioplegic solution (1 mmol/L) infused (at 45 mm Hg) before and every 10 minutes 
during 40 minutes of global ischemia
7. C-EA[F] Continuous coronary perfusion for 40 minutes (at 14 mL/min) of esmolol cardioplegic solution (1 mmol/L)
8. C-EA[P] Continuous coronary perfusion for 40 minutes (at 45 mm Hg) of esmolol cardioplegic solution (1 mmol/L)
STH2, St Thomas’ Hospital solution No. 2; KHB, Krebs-Henseleit buffer. All protocols were followed by a further 60 minutes of reperfusion, when recovery
of myocardial function was measured.
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flow was significantly lower than when esmolol was contin-
uously infused at constant pressure (see Appendix Table 2).
The recovery profile of coronary flow also shows some
interesting differences between groups (Figure 5, B). In par-
ticular, hearts subjected to multiple infusions of STH2
exhibited a hyperemic peak (to 40%) at 5 minutes, with sub-
sequent decline. In contrast, coronary flow in hearts sub-
jected to multiple infusions of esmolol (infused either by
means of constant pressure or constant flow) recovered to
supranormal levels, which increased throughout the 60 min-
utes of reperfusion, reaching significantly higher levels than
all other groups.
The percentage recovery of heart rate was similar in all
groups, reaching approximately 100% of baseline values
(data not shown).
LVEDP. Changes in postischemic LVEDP during 60
minutes of reperfusion are shown in Figure 6; these
changes were similar to those seen in study 1. In general,
LVEDP values mirrored those of LVDP, in which those
hearts that recovered well showed a relatively low value
of LVEDP during reperfusion, whereas hearts that recov-
ered poorly (with a low LVDP) had a higher LVEDP
(groups 1, 2, and 4).
ISCHEMIC CONTRACTURE. Ischemic contracture occurred
only in groups 1, 2, and 4. Time to onset and time to peak of
contracture were significantly delayed by either STH2 or
esmolol infusions compared with global ischemia alone 
(P < .001). In addition, peak contracture was significantly
(P < .01) higher in group 1 than in groups 2 and 4.
Discussion
The present study has demonstrated the following: (1) the
ultra-short-acting β-blocker esmolol induces complete
mechanical and ventricular arrest at a concentration of 1
mmol/L; (2) intermittent esmolol arrest did not enhance the
protection achieved with ICCF; (3) our previous findings
that ICCF was equally as protective as multidose cardiople-
gia can be supported; (4) multidose esmolol arrest was sig-
nificantly more protective than that with other solutions (at
least when hearts were perfused at constant flow); (5) the
method of infusion (constant flow or constant pressure) was
not an influence on recovery for multidose esmolol infusion
(at this ischemic duration) but had a significant effect on
continuous esmolol infusion; and (6) constant flow during
perfusion-reperfusion had a generally detrimental effect.
In the United Kingdom a significant number of surgeons
use ICCF to induce cardiac surgical conditions that allow
coronary revascularization during coronary artery bypass
operations3; this technique was shown to produce good
myocardial protection in recent clinical trials.5,6 However,
because it was unclear from these studies whether ICCF was
itself protective or whether the similar protection to that
achieved with cardioplegia was due to the shorter ischemic
durations (and hence less ischemic injury) associated with
ICCF, our previous study7 was the first (to our knowledge)
to demonstrate that ICCF exerted an intrinsic protection that
was equivalent to that of multidose cardioplegia when the
total ischemic duration was the same. For the present study,
we hypothesized that arrest, rather than VF, during the inter-
mittent crossclamp periods might further enhance the pro-
tective effect of this technique, and we therefore examined
whether the ultra-short-acting β-blocker esmolol might have
a role in this situation.
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Figure 2. Log dose-response curves for LVDP (open squares), ven-
tricular rate (closed diamonds), and atrial rate (open circles), with
increasing concentrations (0.03-3.0 mmol/L) of esmolol in KHB as
a percentage of the baseline value.
Figure 3. Recovery of LVDP (expressed as percentage of the pre-
ischemic control value) during 60 minutes of reperfusion. Values
from 6 hearts per group are given as means ± standard error of the
mean. *P = .048 versus other groups. Open squares, C-GI; filled cir-
cles, S-CP; open circles, M-CP; filled triangles, S-EA; open trian-
gles, M-EA; filled squares, C-EA; filled diamonds, I-GI+VF; open
diamonds, I-EA+GI. Abbreviations are as for Figure 1, study 1.
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β-Blockers and Myocardial Protection
The mechanism of action of β-blockers is widely known21;
they antagonize the binding of catecholamines to the β-
adrenergic receptors of the cell membrane complex, indi-
rectly reducing the number of activated calcium channels
and hence cellular calcium influx. This results in a decrease
in heart rate and myocardial contractility. Although β-block-
ers have been demonstrated to exert a protective effect in the
setting of ischemia in both clinical and experimental stud-
ies, the mechanism by which this is achieved is incomplete-
ly understood. Catecholamine depletion has been shown to
improve recovery of isolated hearts after ischemia,22 and
part of the cardioprotective effect of β-blockers probably
derives from their antagonism to the unfavorable effects of
catecholamines in ischemia; however, several other theories
have been suggested.23,24
Most β-blockers have prolonged negative inotropic
effects that last for hours,12 which renders them unsuitable
for use during acute situations, such as cardiac operations.
However, esmolol, a cardioselective β-adrenergic blocker,
has an extremely short duration of action (half-life of about
9 minutes),13 which is attributable to rapid enzymatic
hydrolysis by blood and tissue esterases,25 making esmolol
a potential candidate for myocardial protection during oper-
ations. Indeed, esmolol was first used to improve myocar-
dial protection during cardiac operations in 1992.14
Subsequently, a number of experimental15,16,26 and clini-
cal17,19,20,27 studies have demonstrated the efficacy of using
esmolol-enriched blood to induce minimal myocardial con-
traction with a flaccid heart, thereby generating conditions
suitable for coronary artery operations while maintaining
coronary perfusion. This use of esmolol was shown to
reduce myocardial edema formation and result in either
equivalent or improved myocardial protection when com-
pared with intermittent cold crystalloid cardioplegia,16,19,27
intermittent cold blood cardioplegia,20 or warm continuous
blood cardioplegia.15,26
Esmolol has previously been shown to induce ventricular
arrest when used at high concentrations. Ede and col-
leagues28 arrested rat hearts at a dose of 1.36 mmol/L. Pirk
and coworkers29 demonstrated that 250 mg/L esmolol
(approximately 0.7 mmol/L) was an optimal concentration
for arrest of the rat heart, whereas 500 mg/L (approximate-
ly 1.4 mmol/L) resulted in reduced recovery of cardiac func-
tion (when washed out). In the present study we observed
similar effects, with an optimal arrest dose of 1.0 mmol/L; a
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Figure 4. Changes in LVEDP during reperfusion (expressed as
absolute value in millimeters of mercury). Values from 6 hearts per
group are given as means ± standard error of the mean. Symbols
and abbreviations are as in Figure 3.
Figure 5. Recovery of LVDP (A) and coronary flow (B; expressed as
percentage of the preischemic control value) during 60 minutes of
reperfusion. Values from 6 hearts per group are given as means ±
standard error of the mean. Open squares, C-GI; filled circles, S-
CP; open circles, M-CP; filled triangles, S-EA; open triangles, M-
EA[F]; filled diamonds, M-EA[P]; open diamonds, C-EA[F]; filled
squares, C-EA[P]. Abbreviations are as for Figure 1, study 2.
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higher dose (3.0 mmol/L) was required for atrial arrest but
led to ventricular dysfunction on washout.
Cardioplegic Infusion Regimen: Effects of Single-Dose,
Multidose, or Continuous Infusion
Multidose cardioplegic infusion enhances protection com-
pared with single-dose infusion,30,31 and this was confirmed
in the present study with both STH2 and esmolol arrest.
This additional benefit has been related to many factors,
including washout of metabolites (eg, lactate, protons, and
inorganic phosphate) that inhibit anaerobic metabolism,
replacement of substrate (particularly oxygen with blood
cardioplegia or the oxygenated KHB with esmolol in the
present study), and limits an evolving edema. Accumulation
of metabolic intermediates cause further disturbances of
energy metabolism, ionic homeostasis, and intracellular pH
regulation32 and eventually leads to loss of cellular viabili-
ty. Recently,33 multiple STH2 infusions were shown to
maintain intracellular sodium (Na+i) concentrations during
ischemia and reperfusion in rat hearts, whereas a single
STH infusion only delayed (and slightly reduced) the rise in
Nai in unprotected hearts. Interestingly, Nai levels correlat-
ed with recovery of function, which were of a similar order
to those observed in the present study. It is tempting to spec-
ulate that similar effects on ionic homeostasis may be occur-
ring in our study with the multiple infusions of esmolol car-
dioplegic solution, particularly in view of the suggested
lidocaine-like activity (sodium-channel blocking effect) of
esmolol at high doses.28 The efficacy of myocardial protec-
tion with β-blockers may require multiple infusion. It has
been demonstrated34 that acute β-blockade was only effec-
tive during relatively short ischemic periods, and this would
be supported by the present data. The short biologic half-life
of esmolol25 would also implicate the importance of multi-
ple reinfusions.
There is increasing use of continuous (blood) cardio-
plegia, which avoids additional ischemia and is particu-
larly useful for patients with severe ischemic disease for
which further ischemic trauma is likely to be detrimental.
Logically, avoidance of ischemia should provide optimal
myocardial protection. However, previous experimental
studies15,16 with continuous esmolol infusion demonstrat-
ed that full protection was only provided for a finite dura-
tion, and extended infusions resulted in depressed func-
tion. This is supported by the present study: hearts
receiving continuous esmolol had a lower recovery than
hearts subjected to global ischemia with multidose
esmolol infusions. It is feasible that total esmolol dose
may influence outcome16 and that the relatively high dose
may exert an adverse effect when infused over long peri-
ods.29 Our preliminary dose-response studies also showed
adverse effects with a higher esmolol dose (3.0 mmol/L),
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TABLE 3. Baseline values (measured after 20 minutes of aerobic perfusion to achieve equilibration) of LVDP, heart rate, and
LVEDP
C-GI S-CP M-CP S-EA M-EA C-EA I-GI+VF I-EA+GI
(group 1) (group 2) (group 3) (group 4) (group 5) (group 6) (group 7) (group 8)
LVDP (mm Hg) 132 ± 10 117 ± 4 130 ± 14 139 ± 11 128 ± 10 114 ± 6 122 ± 3 124 ± 5
Heart rate (beats/min) 289 ± 9 286 ± 5 288 ± 12 269 ± 13 253 ± 7 274 ± 7 279 ± 13 274 ± 19
LVEDP (mm Hg) 4.0 ± 1.0 4.7 ± 1.3 4.2 ± 1.7 3.3 ± 0.5 4.5 ± 1.2 5.8 ± 2.1 4.0 ± 1.5 4.7 ± 1.9
The differences between groups could be due to chance (P > .2). For definition of abbreviations, see text and Table 1.
TABLE 4. Baseline values (measured after 20 minutes of aerobic perfusion to achieve equilibration) of LVDP, coronary flow,
heart rate, and LVEDP
C-GI S-CP M-CP S-EA M-EA[F] M-EA[P] C-EA[F] C-EA[P] 
(group 1) (group 2) (group 3) (group 4) (group 5) (group 6) (group 7) (group 8)
LVDP (mm Hg) 121 ± 8 107 ± 2 133 ± 9 124 ± 9 131 ± 10 107 ± 4 136 ± 13 114 ± 5
Coronary flow (mL/min) 11.3 ± 0.7 12.8 ± 1.8 11.9 ± 0.4 12.4 ± 0.8 11.4 ± 0.7 9.8 ± 0.6 12.2 ± 0.8 9.9 ± 0.3
Heart rate (beats/min) 256 ± 13 247 ± 8 242 ± 11 272 ± 13 272 ± 11 276 ± 11 263 ± 7 257 ± 9
LVEDP (mm Hg) 4.7 ± 1.3 5.8 ± 1.4 4.7 ± 0.6 4.3 ± 0.6 5.3 ± 0.5 6.5 ± 0.6 4.3 ± 0.3 7.5 ± 0.7
Time to mechanical arrest (s) 222 ± 23 35 ± 4*† 31 ± 3*† 47 ± 3* 55 ± 2* 57 ± 2* 59 ± 6* 52 ± 3*
Total infusion volume (mL) — 16.3 ± 0.1 61.5 ± 0.4 28.0 ± 0.0 112.0 ± 0.0 42.7 ± 3.0 560.0 ± 0.0 121.7 ± 3.3
The differences between groups could be due to chance (P > .02). For definition of abbreviations, see text and Table 2.
*P < .001 versus group 1.
†P < .01 versus groups 4 to 8.
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and it is possible that continuous infusion with the lower
dose (1.0 mmol/L) may have had similar effects. It is also
known that esmolol increases coronary vascular resist-
ance, with high doses inducing vasoconstriction. We con-
firmed this in the present study with our observation that
coronary vascular resistance increased during continuous
esmolol infusion at constant flow, and infusion volume
decreased throughout continuous esmolol infusion at con-
stant pressure (data not shown).
Effect of Constant Flow or Constant Pressure
Perfusion-Infusion
In study 1 all hearts were perfused and reperfused at con-
stant flow, and all cardioplegic solutions were infused at the
same constant flow. It has previously been shown35-37 that
postischemic perfusion pressure (or flow rate) plays an
important role in myocardial protection, particularly during
the initial reperfusion period, during which reduced flow
rate (compared with the preischemia period) was shown37 to
enhance postischemic recovery of function. Hearts in study
2 were perfused and reperfused by the more physiologic
method of constant pressure, and effects of administering
cardioplegic solutions by constant flow or constant pressure
were investigated. The results supported the previous find-
ings35-37 that reperfusion pressure is an important compo-
nent of protection. Equivalent groups of hearts had higher
recovery than that in study 1. Also of interest was our find-
ing that continuous infusion of esmolol cardioplegic solu-
tion at constant flow resulted in depressed recovery of func-
tion (Figure 5), an effect that is likely to be related to
increased coronary vascular resistance (see above).
Limitations of the Study
We concede that the present studies were conducted in rat
hearts perfused with a crystalloid solution rather than blood
and that this is a relatively unphysiologic situation. We are
aware that esmolol is metabolized by esterases,25 and con-
sequently, this study would fail to reveal any interaction
between the metabolism of esmolol and the cardioprotective
efficacy of esmolol.
It is also possible that esmolol may have adverse sys-
temic effects that would not be revealed in our study; this
would require investigation in the intact animal. Previous
studies14,19,20,27 have used esmolol clinically during rela-
tively long-term continuous infusion (albeit at lower con-
centrations) with no report of any systemic adverse effects.
Hence, we would speculate that use of short, multiple, high-
dose infusions is unlikely to have major systemic effects,
although this would need verification.
Myocardial ischemic disease is a multifactorial process;
there is a spectrum of injury that affects the method of
myocardial protection. Hearts used in this study were taken
from normal rats, and it is likely that any protective effect of
esmolol would be different in jeopardized hearts with
ischemic injury or disease. In addition, any such hearts are
likely to require prolonged periods of ischemia to correct
the lesion, and the ischemic duration described in this study
is relatively short. Further studies are warranted to investi-
gate these aspects of myocardial protection with esmolol
cardioplegic solution.
Conclusion
Esmolol arrest, rather than VF, during intermittent cross-
clamping did not enhance the myocardial protection of this
technique. Interestingly, however, we observed that multi-
dose esmolol infusions during global ischemia provided
complete protection, and this protection was not influenced
by the method of administration. The method of administra-
tion of esmolol cardioplegic solution was important, how-
ever, during continuous esmolol infusion. The use of
esmolol as a cardioplegic agent may be a beneficial alterna-
tive to conventional cardioplegia or ICCF and would be
applicable to all types of cardiac operations.
References
1. Robinson LA, Schwarz GD, Goddard DB, Fleming WH, Galbraith
TA. Myocardial protection for acquired heart disease surgery: results
of a national survey. Ann Thorac Surg. 1995;59:361-72.
2. Caputo M, Ascione R, Angelini GD, Suleiman MS, Bryan AJ. The end
of the cold era: from intermittent cold to intermittent warm blood car-
dioplegia. Eur J Cardiothorac Surg. 1998;14:467-75.
3. Bonchek LI, Burlingame MW, Vazales BE, Lundy EF, Gassmann CJ.
Applicability of noncardioplegic coronary bypass to high-risk
patients. Selection of patients, technique, and clinical experience in
3000 patients. J Thorac Cardiovasc Surg. 1992;103:230-7.
4. Akins CW. 1987: Early and late results following emergency isolated
The Journal of Thoracic and Cardiovascular Surgery • Volume 122, Number 5   1001
Figure 6. Changes in LVEDP (expressed as absolute value in mil-
limeters of mercury) during 60 minutes of reperfusion. Values from
6 hearts per group are given as means ± standard error of the
mean. *P < .001 versus groups 3 and 5 to 8; #P = .0013 and P = .0037
versus groups 3 and 5, respectively; §P = .011 and P = .026 versus
groups 3 and 5, respectively. Symbols and abbreviations are as in
Figure 5.
ED
ITO
RIA
L
CH
D
G
TS
A
CD
CSP
CSP
TX
myocardial revascularization during hypothermic fibrillatory arrest.
Updated in 1994 by Cary W. Akins, MD. Ann Thorac Surg.
1994;58:1205-6.
5. Musumeci F, Feccia M, MacCarthy PA, Ellis GR, Mammana L, Brinn
F, et al. Prospective randomized trial of single clamp technique versus
intermittent ischaemic arrest: myocardial and neurological outcome.
Eur J Cardiothorac Surg. 1998;13:702-9.
6. Liu Z, Valencia O, Treasure T, Murday AJ. Cold blood cardioplegia or
intermittent cross-clamping in coronary artery bypass grafting? Ann
Thorac Surg. 1998;66:462-5.
7. Bessho R, Chambers DJ. Experimental study of intermittent cross-
clamping with fibrillation and myocardial protection: reduced injury
from shorter cumulative ischemia or intrinsic protective effect? J
Thorac Cardiovasc Surg. 2000;120:528-37.
8. Magee PG, Gardner TJ, Flaherty JT, Bulkley BH, Goldman RA, Gott
VL. Improved myocardial protection with propranolol during induced
ischemia. Circulation. 1980;62(Suppl):I-49-56.
9. Khandoudi N, Percevault-Albadine J, Bril A. Comparative effects of
carvedilol and metoprolol on cardiac ischemia-reperfusion injury. J
Cardiovasc Pharmacol. 1998;32:443-51.
10. Nies AS, Shand DG. Clinical pharmacology of propranolol.
Circulation. 1975;52:6-15.
11. Kloner RA, Kirshenbaum J, Lange R, Antman EM, Braunwald E.
Experimental and clinical observations on the efficacy of esmolol in
myocardial ischemia. Am J Cardiol. 1985;56:40F-8F.
12. Wolman RL, Fiedler MA. Esmolol and beta-adrenergic blockade.
AANA J. 1991;59:541-8.
13. Gorczynski RJ. Basic pharmacology of esmolol. Am J Cardiol.
1985;56:3F-13F.
14. Sweeney MS, Frazier OH. Device-supported myocardial revascular-
ization: safe help for sick hearts. Ann Thorac Surg. 1992;54:1065-70.
15. Mehlhorn U, Allen SJ, Adams DL, Davis KL, Gogola GR, Warters
RD. Cardiac surgical conditions induced by beta-blockade: effect on
myocardial fluid balance. Ann Thorac Surg. 1996;62:143-50.
16. Warters RD, Allen SJ, Davis KL, Geissler HJ, Bischoff I, Mutschler E,
et al. Beta-blockade as an alternative to cardioplegic arrest during car-
diopulmonary bypass. Ann Thorac Surg. 1998;65:961-6.
17. Matsuda H, Fukushima N, Kadoba K, Sawa Y, Nomura F, Kume Y, et
al. Application of ultra short acting beta blockade (esmolol) in pedi-
atric open heart surgery: a trial in total anomalous pulmonary venous
return. J Card Surg. 1996;11:411-6.
18. Mehlhorn U, Sudkamp M. Beta-blockade as an alternative to cardio-
plegia. Thorac Cardiovasc Surg. 1998;46(Suppl 2):302-7.
19. Mehlhorn U, Sauer H, Kuhn-Regnier F, Sudkamp M, Dhein S,
Eberhardt F, et al. Myocardial beta-blockade as an alternative to car-
dioplegic arrest during coronary artery surgery. Cardiovasc Surg.
1999;7:549-57.
20. Kuhn-Regnier F, Natour E, Dhein S, Dapunt O, Geissler HJ, LaRose
K, et al. Beta-blockade versus Buckberg blood-cardioplegia in coro-
nary bypass operation. Eur J Cardiothorac Surg. 1999;15:67-74.
21. Goodman J, Gilman J. Pharmacological basis of therapeutics. 9th ed.
New York: McGraw-Hill; 1995.
22. Gauduel Y, Karagueuzian HS, de Leiris J. Deleterious effects of
endogenous catecholamines on hypoxic myocardial cells following
reoxygenation. J Mol Cell Cardiol. 1979;11:717-31.
23. Nakazawa M, Katano Y, Imai S, Matsushita K, Ohuchi M. Effects of
L- and D-propranolol on the ischemic myocardial metabolism of the
isolated guniea pig heart, as studied by 31P-NMR. J Cardiovasc
Pharmacol. 1982;4:700-4.
24. Nagai S, Miyazaki Y, Ogawa K, Satake T, Sugiyama S, Ozawa T. The
effects of beta-blocking agents on mitochondrial function in ischemic
myocardium. Jpn Circ J. 1984;48:32-6.
25. Quon CY, Stampfli HF. Biochemical properties of blood esmolol
esterase. Drug Metab Dispos. 1985;13:420-4.
26. Geissler HJ, Davis KL, Laine GA, Ostrin EJ, Mehlhorn U, Hekmat K,
et al. Myocardial protection with high-dose beta-blockade in acute
myocardial ischemia. Eur J Cardiothorac Surg. 2000;17:63-70.
27. Hekmat K, Clemens RM, Mehlhorn U, Geissler HJ, Kuhn-Regnier F,
de Vivie ER. Emergency coronary artery surgery after failed PTCA:
myocardial protection with continuous coronary perfusion of beta-
blocker-enriched blood. Thorac Cardiovasc Surg. 1998;46:333-8.
28. Ede M, Ye J, Gregorash L, Summers R, Pargaonkar S, LeHouerou D,
et al. Beyond hyperkalemia: beta-blocker-induced cardiac arrest for
normothermic cardiac operations. Ann Thorac Surg. 1997;63:721-7.
29. Pirk J, Kolar F, Ost’adal B, Sedivy J, Stambergova A, Kellovsky P. The
effect of the ultrashort beta-blocker esmolol on cardiac function recov-
ery: an experimental study. Eur J Cardiothorac Surg. 1999;15:199-203.
30. Engelman RM, Auvil J, O’Donoghue MJ, Levitsky S. The significance
of multidose cardioplegia and hypothermia in myocardial preservation
during ischemic arrest. J Thorac Cardiovasc Surg. 1978;75:555-63.
31. Lucas SK, Elmer EB, Flaherty JT, Prodromos CC, Bulkley BH, Gott
BL, et al. Effect of multiple-dose potassium cardioplegia on myocar-
dial ischemia, return of ventricular function, and ultrastructural preser-
vation. J Thorac Cardiovasc Surg. 1980;80:102-10.
32. Rovetto MJ, Lamberton WF, Neely JR. Mechanisms of glycolytic
inhibition in ischemic rat hearts. Circ Res. 1975;37:742-51.
33. Schepkin VD, Choy IO, Budinger TF, Young JN, DeCampli WM.
Multi-dose crystalloid cardioplegia preserves intracellular sodium
homeostasis in myocardium. J Mol Cell Cardiol. 1999;31:1643-51.
34. Toleikis PM, Tomlinson CW. Myocardial functional preservation during
ischemia: influence of beta blocking agents. Mol Cell Biochem.
1997;176:205-10.
35. Okamoto F, Allen BS, Buckberg GD, Bugyi H, Leaf J. Reperfusion
conditions: importance of ensuring gentle versus sudden reperfusion
during relief of coronary occlusion. J Thorac Cardiovasc Surg.
1986;92:613-20.
36. Hori M, Kitakaze M, Sato H, Takashima S, Iwakura K, Inoue M, et al.
Staged reperfusion attenuates myocardial stunning in dogs. Role of
transient acidosis during early reperfusion. Circulation.
1991;84:2135-45.
37. Takeo S, Liu JX, Tanonaka K, Nasa Y, Yabe K, Tanahashi H, et al.
Reperfusion at reduced flow rates enhances postischemic contractile
recovery of perfused heart. Am J Physiol. 1995;268:H2384-95.
Cardiopulmonary Support and Physiology Bessho and Chambers
1002 The Journal of Thoracic and Cardiovascular Surgery • November 2001
Bessho and Chambers Cardiopulmonary Support and Physiology
TX
CS
P
CS
P
A
CD
CH
D
G
TS
ED
IT
O
RI
A
L
The Journal of Thoracic and Cardiovascular Surgery • Volume 122, Number 5   1003
APPENDIX TABLE 1. Results of post hoc analysis for recovery of LVDP after 60 minutes of reperfusion for study 1
C-GI S-CP M-CP S-EA M-EA C-EA I-GI+VF I-EA+GI 
(group 1) (group 2) (group 3) (group 4) (group 5) (group 6) (group 7) (group 8)
C-GI (group 1) — .0057 <.0001 .9132 <.0001 <.0001 <.0001 <.0001
S-CP (group 2) .0057 — <.0001 .0076 <.0001 <.0001 <.0001 <.0001
M-CP (group 3) <.0001 <.0001 — <.0001 .0099 .4545 .8842 .4562
S-EA (group 4) .9132 .0076 <.0001 — <.0001 <.0001 <.0001 <.0001
M-EA (group 5) <.0001 <.0001 .0099 <.0001 — .0012 .0143 .0484
C-EA (group 6) <.0001 <.0001 .4545 <.0001 .0012 — .3724 .139
I-GI+VF (group 7) <.0001 <.0001 .8842 <.0001 .0143 .3724 — .5481
I-EA+GI (group 8) <.0001 <.0001 .4562 <.0001 .0484 .139 .5481 —
For definition of abbreviations, see Table 1.
APPENDIX TABLE 2. Results of post hoc analysis for recovery of LVDP after 60 minutes of reperfusion for study 2
C-GI S-CP M-CP S-EA M-EA[F] M-EA[P] C-EA[F] C-EA[P] 
(group 1) (group 2) (group 3) (group 4) (group 5) (group 6) (group 7) (group 8)
C-GI (group 1) — .0011 <.0001 .3847 <.0001 <.0001 <.0001 <.0001
S-CP (group 2) .0011 — .0013 .0116 <.0001 <.0001 .2401 .0005
M-CP (group 3) <.0001 .0013 — <.0001 .2618 .1990 .0288 .7395
S-EA (group 4) .3847 .0116 <.0001 — <.0001 <.0001 .0004 <.0001
M-EA[F] (group 5) <.0001 <.0001 .2618 <.0001 — .8676 .0015 .4265
M-EA[P] (group 6) <.0001 <.0001 .1990 <.0001 .8676 — .0009 .3373
C-EA[F] (group 7) <.0001 .2401 .0288 .0004 .0015 .0009 — .0129
C-EA[P] (group 8) <.0001 .0005 .7395 <.0001 .4265 .3373 .0129 —
For definitions of abbreviations, see Table 2.
